Caesarstone reported 676 silica exposure lawsuits as of December 31, 2025. Its October 27 filing reports one October jury award of approximately $67.3 million, with approximately $46.5 million apportioned to the company if assessed without modification; Business Insurance reports a separate $33 million verdict five days earlier.
Caesarstone, the Israel-based countertop maker, faced 676 lawsuits alleging silica dust injuries as of December 31, 2025; Business Insurance reports two October verdicts totaling about $100 million. One plaintiff, stone fabricator Dennys Rene Rivas-Williams, is living on transplanted lungs that are already failing, the publication reported. In an October 27 Securities and Exchange Commission filing, Caesarstone reported that a jury in California awarded him approximately $67.3 million and assigned the company 69.1% of fault. Caesarstone estimated its share at approximately $46.5 million if assessed without modification, close to its $47.3 million provision for probable and estimable silica claim exposure as of December 31, 2025, and said it was considering its available actions.
Caesarstone has disputed an earlier trial result. In its 2025 annual report, it wrote of an August 2024 verdict, “We strongly disagree with the jury’s verdict” and said the jury had failed to acknowledge its efforts to warn and educate fabricators about safe practices. The annual report says the jury awarded $52.4 million and allocated 15% of fault to Caesarstone. Elsewhere, it says Caesarstone U.S. was apportioned approximately $13.0 million of that award. The annual report also says Caesarstone believes it has substantial defenses to 422 other individual U.S. product liability claims and will continue to vigorously defend them.
The 3 sources behind this story: 2 SEC filings and 1 other source, each linked with what it shows. Free with the weekly Litigation Sentinel brief.
The case with an October 26 jury verdict, *Dennys Rene Rivas-Williams v. A&A Granite Marble, et al.*, was tried in the Superior Court of California, County of Los Angeles, as part of a coordinated proceeding for silica exposure cases. Caesarstone’s filing records both the approximately $67.3 million award to Rivas-Williams and the approximately $46.5 million share allocated to the company. The first is the jury’s total damages figure. The second is Caesarstone’s estimate of its portion if the verdict is assessed without modification.
Business Insurance reported the total as $67.7 million. Its account says Rivas-Williams was diagnosed with silicosis at 35, received a double lung transplant two years later, and is expected to need another transplant. It also reports that the jury found Caesarstone’s product design defective and awarded $60 million for losses other than medical bills and earnings.
The allocation matters beyond this trial. As of December 31, 2025, Caesarstone had recorded a $47.3 million provision for probable and estimable exposure from pending silica claims in Israel, Australia and the United States, its annual report says. P&L translation: Caesarstone’s estimated share of one plaintiff’s award, approximately $46.5 million if unmodified, sits within $1 million of that year-end provision. The two figures cover different dates and different sets of claims, and the verdict remains subject to the actions the company says it is considering.
Free weekly intelligence for executives responsible for litigation exposure: the named decision-makers, dollar exposure, operating consequence, and next development.
Business Insurance reported that a different jury awarded $33 million on October 21 to another stone fabricator with silicosis. It reports that the jury assigned Caesarstone and its United States subsidiary 22% of responsibility and the fabrication shop, Lucky Stone, 70%.
The same account says the second jury found Caesarstone’s product defective and rejected its defense that misuse caused the harm. Added to the approximately $67.3 million in the company’s filing, the reported $33 million award brings the two October verdicts to about $100 million in total damages, before any allocation of fault.
The company’s own case count sets the scale. Of the 676 lawsuits Caesarstone reported as of December 31, 2025, 427 were in the United States, 151 in Australia and 98 in Israel. Its annual report said that 387 individual U.S. claims had potential losses it could not reasonably estimate. It also recorded a complete defense verdict in a California trial in May 2025. Caesarstone said it expected additional verdicts.
Caesarstone’s October filing puts the Rivas-Williams result beside its expectations about post-trial remedies, an appeal, its financial condition and its ability to obtain additional financing. It is the company’s own account of the risks it is assessing.
Insurance is another unresolved part of the money path. In its annual report, Caesarstone said it had been unable to obtain product liability insurance for new silica exposure claims in several jurisdictions. It also described disputes with insurers over United States coverage and said it had recognized no insurance receivable for pending United States silica claims. Those disputes leave the amount it may ultimately recover from insurance unsettled.
The next choice belongs to Caesarstone. It says it is considering its available actions after the Rivas-Williams verdict, and its filing discusses possible post-trial remedies and an appeal. Its filings trace a United States trial record from a 15% fault share of a $52.4 million verdict in August 2024, through a complete defense verdict in May 2025, to a 69.1% share of approximately $67.3 million in October. Rivas-Williams, who Business Insurance reports is expected to need another transplant, holds the largest of those awards.
The readiness check has five questions about your reported litigation practices. Use the summary to choose an operating question to explore.
Take the 2-minute readiness check →Free weekly intelligence for executives responsible for litigation exposure: the named decision-makers, dollar exposure, operating consequence, and next development.